Neuraxis, Inc. (NRXS) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Neuraxis, Inc. is a growth-stage medical device company specializing in neuromodulation therapies, primarily marketing the IB-STIM device for functional abdominal pain in children. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of the reporting date, there were 6,980,227 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Net Sales | $666,625 | $477,460 | $1,924,760 | $1,928,590 |
| Gross Profit | $569,575 | $410,173 | $1,667,811 | $1,697,590 |
| Gross Margin | 85.4% | 85.9% | 86.7% | 88.0% |
| Operating Loss | $(1,651,273) | $(3,022,339) | $(5,690,225) | $(5,041,290) |
| Net Loss | $(1,755,234) | $(8,625,363) | $(6,793,596) | $(13,034,385) |
| Cash and Equivalents | $260,885 (as of Sept 30, 2024) | |||
| Working Capital Deficit | $(2,032,284) (as of Sept 30, 2024) | |||
| Notes Payable | $147,688 (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2024 net sales increased 39.6% year-over-year to $666,625, driven by volume growth from new insurance-reimbursed customers and financial assistance programs. YTD sales remained flat (-0.2%) compared to 2023.
- Margin Compression: Gross margin decreased slightly to 85.4% in Q3 (from 85.9%) and 86.7% YTD (from 88.0%). This is attributed to a higher mix of discounted sales through financial assistance programs for uninsured patients.
- Expense Reduction: Q3 General and Administrative (G&A) expenses decreased 38.2% to $2.05 million, primarily due to the absence of one-time 2023 post-IPO consulting fees and incentive bonuses. However, YTD G&A increased 10.8% due to new public company costs, severance charges, and stock-based compensation.
- Net Loss Improvement: Net loss decreased significantly by 79.7% in Q3 and 47.9% YTD compared to 2023. This improvement is largely due to the elimination of non-cash charges related to debt extinguishment and derivative liabilities that occurred during the 2023 IPO.
- Capital Structure: In August 2024, $4.935 million of convertible promissory notes were mandatorily converted into 2,073,524 shares of Series B Preferred Stock.
Outlook, Risks, and Contingencies
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $55.35 million and a working capital deficit of $2.03 million. Future operations depend on securing insurance coverage for the IB-STIM device and raising additional capital.
- Liquidity: Cash on hand is $260,885. The company relies on financing activities (convertible notes and equity) to fund operations, as operating cash flows remain negative ($4.34 million used YTD).
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting due to limited segregation of duties and resource constraints. A restatement of prior period financial statements was noted.
- Litigation: The company is defending against two lawsuits alleging RICO violations and fraudulent misrepresentation regarding Medicare billing for its NeuroStim device. One case was dismissed at the district court level but is under appeal; the other has partial claims dismissed with remaining claims pending.
- Subsequent Events: In November 2024, the company entered into a $5 million investment agreement with a life sciences fund, expected to close mid-November.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $260,885 cash balance against the $2.03 million working capital deficit and ongoing burn rate.
- Financing Status: Confirm the closing of the $5 million investment agreement mentioned in subsequent events and the terms of the Series B Preferred Stock.
- Insurance Adoption: Assess the progress of insurance carrier adoption for the IB-STIM device, which management cites as the primary driver for future revenue.
- Internal Controls: Review the remediation plan for material weaknesses in internal controls and the timeline for achieving compliance with Section 404 of the Sarbanes-Oxley Act.
- Litigation Exposure: Monitor the status of the pending RICO and fraud lawsuits and potential financial impact if defenses are unsuccessful.